YU73503A - Preparati insulina koji ne sadrže cink ili sadrže male količine cinka i koji imaju poboljšanu stabilnost - Google Patents

Preparati insulina koji ne sadrže cink ili sadrže male količine cinka i koji imaju poboljšanu stabilnost

Info

Publication number
YU73503A
YU73503A YU73503A YUP73503A YU73503A YU 73503 A YU73503 A YU 73503A YU 73503 A YU73503 A YU 73503A YU P73503 A YUP73503 A YU P73503A YU 73503 A YU73503 A YU 73503A
Authority
YU
Yugoslavia
Prior art keywords
zinc
insulin
combinations
contain
small quantity
Prior art date
Application number
YU73503A
Other languages
English (en)
Inventor
Peter Boderke
Original Assignee
Aventis Pharma Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh. filed Critical Aventis Pharma Deutschland Gmbh.
Priority to MEP-2008-608A priority Critical patent/ME00408B/me
Publication of YU73503A publication Critical patent/YU73503A/sh
Publication of RS51579B publication Critical patent/RS51579B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Abstract

Ovaj pronalazak se odnosi na neku farmaceutsku formulaciju koja sadrži neki polipeptid, koji je izabran iz grupe koja obuhvata insulin, neki metabolit insulina, neki analog insulina, neki derivat insulina ili njihove kombinacije; neki tenzid ili kombinacije više tenzida, po izboru neko sredstvo za konzerviranje ili kombinacije više sredstava za konzerviranje; i po izboru neko sredstvo za izotonizaciju, pufer ili druge pomoćne supstance ili njihove kombinacije, pri čemu farmaceutska formulacija ne sadrži cink ili sadrži neznatne količine cinka. Pronalazak se odnosi isto tako na proizvodnju takvih insulinskih preparata.[The invention relates to a pharmaceutical formulation containing: a polypeptide selected from a group containing insulin, an insulin metabolite, an insulin analog, an insulin derivative or combinations thereof; a surfactant or combinations of several surfactants; optionally, a preservative or combinations of several preservatives, and; optionally, an isotonizing agent, buffers or additional adjuvants or combinations thereof, whereby the pharmaceutical formulation does not contain any zinc or only a small quantity of zinc. The invention also relates to the production of insulin preparations of the aforementioned type.
YU73503A 2001-03-23 2002-03-09 Preparati insulina koji ne sadrže cink ili sadrže male količine cinka i koji imaju poboljšanu stabilnost RS51579B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-2008-608A ME00408B (me) 2001-03-23 2002-03-09 Preparati insulina koji ne sadrže cink ili sadrže male količine cinka koji imaju poboljšanu stabilnost

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10114178A DE10114178A1 (de) 2001-03-23 2001-03-23 Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
PCT/EP2002/002625 WO2002076495A1 (de) 2001-03-23 2002-03-09 Zinkfreie und zinkarme insulinzubereitungen mit verbesserter stabilität

Publications (2)

Publication Number Publication Date
YU73503A true YU73503A (sh) 2006-05-25
RS51579B RS51579B (sr) 2011-08-31

Family

ID=7678654

Country Status (32)

Country Link
US (5) US6960561B2 (sh)
EP (2) EP1381385B1 (sh)
JP (1) JP4231292B2 (sh)
KR (2) KR100987311B1 (sh)
CN (1) CN1273187C (sh)
AR (2) AR033059A1 (sh)
AT (1) ATE497777T1 (sh)
AU (1) AU2002302409B2 (sh)
BR (1) BRPI0208210B8 (sh)
CA (1) CA2441260C (sh)
CY (2) CY1111413T1 (sh)
DE (2) DE10114178A1 (sh)
DK (2) DK1381385T3 (sh)
ES (2) ES2360505T3 (sh)
HK (1) HK1061521A1 (sh)
HR (1) HRP20030765B1 (sh)
HU (1) HU228847B1 (sh)
IL (2) IL158057A0 (sh)
ME (1) ME00408B (sh)
MX (1) MXPA03007942A (sh)
MY (1) MY129417A (sh)
NO (1) NO326780B1 (sh)
NZ (1) NZ528335A (sh)
PE (1) PE20020968A1 (sh)
PL (1) PL205465B1 (sh)
PT (2) PT2289539E (sh)
RS (1) RS51579B (sh)
RU (1) RU2311922C2 (sh)
SI (1) SI1381385T1 (sh)
TW (1) TWI301761B (sh)
WO (1) WO2002076495A1 (sh)
ZA (1) ZA200306637B (sh)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000076419A (ko) * 1997-03-20 2000-12-26 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 폐 투여용 무아연 인슐린 결정 조성물
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20050250676A1 (en) * 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DE10250297A1 (de) * 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
US7658721B2 (en) * 2004-01-16 2010-02-09 Biodel Inc. Sublingual drug delivery device
CA2555921A1 (en) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
ES2398838T3 (es) * 2004-03-12 2013-03-22 Biodel, Inc. Composiciones de suministro de fármacos de acción rápida
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US7875700B2 (en) 2004-07-19 2011-01-25 Biocon Limited Cation complexes of insulin compound conjugates, formulation and uses thereof
JP2006087815A (ja) * 2004-09-27 2006-04-06 Canon Inc 噴霧方法および該方法に基づく噴霧装置
US20060194762A1 (en) * 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1969004B1 (en) * 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
MX2008013165A (es) 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
EP2152243A2 (en) * 2007-04-30 2010-02-17 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
WO2009065126A2 (en) * 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
WO2009075859A2 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
KR101239008B1 (ko) * 2008-03-31 2013-03-04 한양대학교 산학협력단 바일산 유도체 및 그의 응용
JP2010063762A (ja) * 2008-09-12 2010-03-25 Yoshiharu Masui 抗菌消臭剤
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
RU2540922C2 (ru) 2008-10-30 2015-02-10 Ново Нордиск А/С Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
KR101775000B1 (ko) * 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
DK2451437T3 (en) * 2009-07-06 2017-02-13 Sanofi Aventis Deutschland Aqueous INSULIN PREPARATIONS CONTAINING METHIONIN
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014010139A2 (pt) 2011-10-27 2017-04-25 Univ Case Western Reserve formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
DK2983697T3 (en) 2013-04-03 2019-02-25 Sanofi Sa TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
TW201605489A (zh) * 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
BR112016015851A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
CN105899191B (zh) 2014-01-09 2020-06-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US11352406B2 (en) 2015-08-25 2022-06-07 Novo Nordisk A/S Insulin derivatives and the medical uses hereof
EP3341401A1 (en) 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341402A1 (en) 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN105749292A (zh) * 2016-02-29 2016-07-13 苏州市贝克生物科技有限公司 促进胰岛素吸收的组合物及其制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
ES2954180T3 (es) 2016-09-29 2023-11-20 Arecor Ltd Formulación farmacéutica que comprende un compuesto de insulina
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
MX2019014195A (es) 2017-06-01 2020-01-27 Lilly Co Eli Composiciones de insulina de rapida accion.
CA3094304A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CA3094308A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US20210038506A1 (en) 2018-04-04 2021-02-11 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
BR112022007593A2 (pt) 2019-10-25 2022-08-23 Cercacor Lab Inc Compostos indicadores, dispositivos que compreendem compostos indicadores e métodos de fabricação e uso dos mesmos
JP6995284B2 (ja) 2019-12-11 2022-01-14 ノヴォ ノルディスク アー／エス 新規インスリン類似体およびそれらの使用
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3758683A (en) * 1971-04-30 1973-09-11 R Jackson Insulin product
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3064888D1 (en) * 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
DE3033127A1 (de) 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt Neue analoga des insulins
AU558474B2 (en) 1981-07-17 1987-01-29 Nordisk Insulinlaboratorium A stable aqueous, therapeutic insulin preparation and a process for preparing it
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327713A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Wasserloesliche disazoverbindungen, verfahren zu deren herstellung und ihre verwendung als farbstoffe
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
CA1244347A (en) * 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
ATE50502T1 (de) 1984-06-09 1990-03-15 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
KR860001166B1 (ko) * 1984-06-15 1986-08-20 곽성일 신발 결착용 구멍쇠의 제조방법
DE3440988A1 (de) * 1984-11-09 1986-07-10 Hoechst Ag, 6230 Frankfurt Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
IL78425A (en) * 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
DE3526995A1 (de) 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3541856A1 (de) 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
US5496924A (en) 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DE3544295A1 (de) * 1985-12-14 1987-06-19 Bayer Ag Thermoplastische formmassen mit hoher kriechstromfestigkeit
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
IE62879B1 (en) 1987-02-25 1995-03-08 Novo Nordisk As Novel insulin derivatives
US5034415A (en) * 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
DE3726655A1 (de) 1987-08-11 1989-02-23 Hoechst Ag Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5358857A (en) * 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
DE69129110T2 (de) 1990-05-10 1998-12-10 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US6468959B1 (en) * 1991-12-05 2002-10-22 Alfatec-Pharm Gmbh Peroral dosage form for peptide containing medicaments, in particular insulin
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
WO1993010768A1 (de) * 1991-12-05 1993-06-10 Alfatec-Pharma Gmbh Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
DK0600372T3 (da) 1992-12-02 1997-08-11 Hoechst Ag Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
AU680462B2 (en) 1992-12-18 1997-07-31 Eli Lilly And Company Insulin analogs
DE4400709B4 (de) * 1993-01-13 2005-06-23 Denso Corp., Kariya Schraubenfestziehvorrichtung
US5606203A (en) * 1993-01-20 1997-02-25 Kabushiki Kaisha Toshiba Semiconductor device having Al-Cu wiring lines where Cu concentration is related to line width
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
DE4405179A1 (de) 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
CA2196184C (en) 1994-09-09 2009-06-09 Yasutaka Igari Sustained release preparation containing metal salt of a peptide
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
AU6011496A (en) 1995-06-08 1997-01-09 Therexsys Limited Improved pharmaceutical compositions for gene therapy
AU6242096A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
DE19545257A1 (de) * 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
DE19707245A1 (de) * 1997-02-25 1998-08-27 Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh Verfahren zur Herstellung einer elektrischen Glühlampe
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
KR20000076419A (ko) * 1997-03-20 2000-12-26 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 폐 투여용 무아연 인슐린 결정 조성물
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
DE69826705T2 (de) 1997-11-12 2006-02-23 Alza Corp., Palo Alto Verfahren zur dermalen verabreichung von polypeptiden
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
CA2346884A1 (en) 1998-10-16 2000-04-27 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6635617B1 (en) * 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
DE69920767T2 (de) 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
US6489292B1 (en) * 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
JP2002529514A (ja) 1998-11-18 2002-09-10 ノボ ノルディスク アクティーゼルスカブ フェノール及びクレゾールを要さない安定なインスリン水性調製物
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU5936400A (en) * 1999-06-04 2000-12-28 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
ATE296091T1 (de) 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
AU2001264789A1 (en) 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20050013867A1 (en) 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia

Also Published As

Publication number Publication date
BR0208210A (pt) 2004-03-09
BRPI0208210B8 (pt) 2021-05-25
MXPA03007942A (es) 2004-04-02
EP1381385B1 (de) 2011-02-09
MY129417A (en) 2007-03-30
RU2311922C2 (ru) 2007-12-10
DK1381385T3 (da) 2011-06-06
DE50214903D1 (de) 2011-03-24
IL158057A0 (en) 2004-03-28
ATE497777T1 (de) 2011-02-15
WO2002076495A1 (de) 2002-10-03
ES2393180T3 (es) 2012-12-19
JP4231292B2 (ja) 2009-02-25
US20070155653A1 (en) 2007-07-05
CY1111413T1 (el) 2015-08-05
BRPI0208210B1 (pt) 2018-05-02
EP2289539B1 (de) 2012-09-19
SI1381385T1 (sl) 2011-05-31
TWI301761B (en) 2008-10-11
HU228847B1 (en) 2013-06-28
CY1113318T1 (el) 2016-04-13
NO20034125L (no) 2003-11-11
PL362800A1 (en) 2004-11-02
NO20034125D0 (no) 2003-09-16
HK1061521A1 (en) 2004-09-24
PT2289539E (pt) 2012-11-20
CA2441260C (en) 2011-04-26
CN1498113A (zh) 2004-05-19
PL205465B1 (pl) 2010-04-30
KR20100061868A (ko) 2010-06-09
IL158057A (en) 2013-10-31
US20050187142A1 (en) 2005-08-25
US7205277B2 (en) 2007-04-17
PE20020968A1 (es) 2002-12-10
ES2360505T3 (es) 2011-06-06
US20050187143A1 (en) 2005-08-25
KR100987311B1 (ko) 2010-10-13
DE10114178A1 (de) 2002-10-10
AR033059A1 (es) 2003-12-03
NO326780B1 (no) 2009-02-16
RU2003131187A (ru) 2005-03-10
US20030004096A1 (en) 2003-01-02
NZ528335A (en) 2005-03-24
EP1381385A1 (de) 2004-01-21
US7452860B2 (en) 2008-11-18
US6960561B2 (en) 2005-11-01
PT1381385E (pt) 2011-03-17
MEP60808A (en) 2011-05-10
HRP20030765A2 (en) 2005-06-30
CN1273187C (zh) 2006-09-06
US7696162B2 (en) 2010-04-13
US20090186807A1 (en) 2009-07-23
RS51579B (sr) 2011-08-31
JP2004523589A (ja) 2004-08-05
US7205276B2 (en) 2007-04-17
ME00408B (me) 2011-10-10
EP2289539A1 (de) 2011-03-02
HUP0303596A3 (en) 2005-11-28
AR096376A2 (es) 2015-12-23
KR20040011483A (ko) 2004-02-05
ZA200306637B (en) 2004-05-07
AU2002302409B2 (en) 2007-01-04
CA2441260A1 (en) 2002-10-03
HRP20030765B1 (en) 2011-10-31
HUP0303596A2 (hu) 2004-01-28
DK2289539T3 (da) 2013-01-14

Similar Documents

Publication Publication Date Title
MXPA03007942A (es) Preparaciones de insulina exentas de zinc y con bajo contenido de zinc, que tienen una estabilidad mejorada.
RS105704A (sr) Kiseli preparati insulina sa poboljšanom stabilnošću
MY145753A (en) Novel cyclosporin analog formulations
EA200301275A1 (ru) Капсулы для ингаляции
IL153297A0 (en) Compounds and compositions for delivering active agents
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
WO2004110352A3 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
MXPA03011793A (es) Formulaciones de interferon.
CA2420874A1 (en) Active ingredient combinations with insecticidal and acaricidal properties
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
CA2333601A1 (en) Surfactant for use in external preparations for skin and external preparation for skin containing the same
WO2003105767A3 (en) ANTIFUNGAL PARENTERAL PRODUCTS
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
WO2005027822A3 (en) Stabilized formulations of phosphatidylserine
EP2308479A3 (en) Compounds and compositions for delivering active agents
WO2002015959A3 (en) Compounds and compositions for delivering active agents
HUP0402077A2 (hu) Fungicid hatóanyag-kombinációk
CA2366679A1 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
WO2001093816A3 (en) Stabilized compositions containing oxygen-labile active agents
HUP0001970A2 (hu) Gombaellenes szert és foszfolipidet tartalmazó készítmények
IL155788A (en) A highly purified ifn – β active and mannitol-containing preparation, a method to make an improved stability of ifn – β active, and a method to enhance the stability of ifn – β in biologically active formulation.
MY131488A (en) Low dose liquid entecavir formulations and use
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi